It’s Wednesday, so I would like to tell you about some cool things I learned this past week about the science of how exercise can be used as a treatment for three common ailments.
First, some background about exercise: The great thing about exercising every day that you eat is that this magic potion is not a shot or a pill. It does not involve a doctor burning or squishing anything in your body. There are no HIPAA forms, no insurance pre-certifications, and not even a co-pay. It’s as we say, easy and free. And drum roll please…exercise is active—not passive.
Here’s the Mandrola take on how exercise might treat three specific medical conditions: Read more »
*This blog post was originally published at Dr John M*
For real… at least in mice, but has potential for human application if the promise holds out!
MIT researchers have developed a radical new approach to eradicating viral infections no matter what the virus may be… common cold, HIV, Ebola, polio, dengue fever, etc.
The usual anti-viral antibiotics in use today target the viral replication process which unfortunately often fails with time as the virus adapts and develops resistance to the medication.
The new medication dubbed “DRACO” (Double-stranded RNA Activated Caspase Oligomerizers) approaches viral infections using a totally different approach. Read more »
*This blog post was originally published at Fauquier ENT Blog*
[Recently] I participated in a panel discussion at the Northeast Conference of Science and Skepticism (NECSS) with John Snyder, Kimball Atwood, and Steve Novella, who also reported on the conference. What I mentioned to some of the attendees is that I had managed to combine NECSS with a yearly ritual that I seldom miss, namely the yearly meeting of the American Association for Cancer Research (AACR) meeting.
There are two huge cancer meetings every year — AACR and the annual meeting of the American Society for Clinical Oncology (ASCO). AACR is the meeting dedicated to basic and translational research. ASCO, as the word “clinical” in its name implies, is devoted mainly to clinical research.
Personally, being a translational researcher myself and a surgeon, I tend to prefer the AACR meeting over ASCO, not because ASCO isn’t valuable, but mainly because ASCO tends to be devoted mostly to medical oncology and chemotherapy, which are not what I do as a surgeon. Each meeting draws between 10,000 to 15,000 or even more clinicians and researchers dedicated to the eradication of cancer. Read more »
*This blog post was originally published at Science-Based Medicine*